1 Patient values or values from the general public.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Quality of life in relation to costs
1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
Caring. Carers Paid Social Carers: Staff who work with people in residential care homes, in day centres and who provide care in someone’s home Unpaid.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
A Method to Estimate the Burden of Foodborne Illness Angela Lasher CFSAN-FDA
By Janet Bowen. WHAT IS DISCHARGE PLANNING Discharge planning is the process by which the patient is assisted to develop a plan of care for ongoing maintenance.
EHC Workshop on Economics and HTA’s for EU Member Organisations
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
Outcomes that matter to patients: Patient Reported Outcome Measures (PROMs) for people with renal replacement UK Renal Registry 2015 Annual Audit Meeting.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
Quality of life Assessment introduction
1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
What have we learned? What is next? Panel B: Functional Capacity, Quality of Life and Outcomes H.Functional Capacity I.Neurocognitive Assessment J.Quality.
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
© 2010 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Pharmacoeconomics Research: Its Role in Clinical Trials Kent H Summers, PhD Associate Professor Purdue University, School of Pharmacy May 14, 2008.
Presentations: Quantifying the impact of adverse events on HRQOL early after implant Patient selection and estimation of prognosis using health status.
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Quality Adjusted Life Years (QALY)
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
The experience of Denmark with Summary Measures of Population Health 7 th Meeting of the Task Force on Health Expectancies Luxembourg, 2 December 2008.
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Governance and Public Policy: a NICE example John Brazier Professor of Health Economics, ScHARR, University of Sheffield, UK With thanks to Matt Stevenson.
1 Scale recalibration effects in dementia patients and their proxies Sander Arons Dept. of Epidemiology, Biostatistics and HTA Radboud University Nijmegen.
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
Introduction to decision analysis Jouni Tuomisto THL.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
Introduction to decision analysis Jouni Tuomisto THL.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
Analyses of extended set questions using the U.S. National Health Interview Survey Mitchell Loeb / Jennifer Madans National Center for Health Statistics/
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
 Agreed upon fees paid for coverage of medical benefits for a defined benefit period. Premiums can be paid by employers, unions, employees, or shared.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
Canadian TTO Valuations of the EQ-5D-5L: East versus West Differences
Table 1. Characteristics of generic HRQOL assessments in adult physical activity research Peter D. Hart et al. Systematic Review of Health-Related Quality.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
M. Dakoutrou, V. Gerovasili, G. Sidiras, I. Patsaki, A. Kouvarakos, S
Prof. Dr. Jan J.V. Busschbach
Risk Management/Insurance, Real Estate and Legal Studies
The valuation of disease-specific questionnaires for QALY analysis
Is healthcare any good for patients
Title: What do patients say?
Student Champions Learning about NICE
Impact of Mode and Order of Administration on Generic HRQOL Scores
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

1 Patient values or values from the general public

2 The clinical perspective  Quality of life is subjective…..  “Given its inherently subjective nature, consensus was quickly reached that quality of life ratings should, whenever possible, be elicited directly from patients themselves. “ (Neil Aaronson, in B. Spilker: Quality of life and Pharmacoeconomics in Clinical Trails, 1996, page 180)  …therefore ask the patient!

3 A problem in the patient perspective….  Stensman  Scan J Rehab Med 1985;17:  Scores on a visual analogue scale  36 subjects in a wheelchair  36 normal matched controls  Mean score  Wheelchair: 8.0  Health controls: 8.3 Healthy Death

4 The economic perspective  In a normal market: the consumer values count  The patient seems to be the consumer  Thus the values of the patients….  If indeed health care is a normal market…  But is it….?

5 Health care is not a normal market  Supply induced demands  Government control  Financial support (egalitarian structure)  Patient  Consumer  The patient does not pay  Consumer = General public  Potential patients are paying  Health care is an insurance market  A compulsory insurance market

6 Health care is an insurance market  Values of benefit in health care have to be judged from a insurance perspective  Who values should be used the insurance perspective?

7 Who determines the payments of unemployment insurance?  Civil servant  Knowledge: professional  But suspected for strategical answers more money, less problems identify with unemployed persons  The unemployed persons themselves  Knowledge: specific  But suspected for strategical answers  General public (politicians)  Knowledge: experience  Payers

8 Who’s values (of quality of life) should count in the health insurance?  Doctors  Knowledge: professional  But suspected for strategical answers See only selection of patient Identification with own patient  Patients  Knowledge: disease specific  But suspected for strategical answers  But coping  General public  Knowledge: experience  Payers  Like costs: the societal perspective

9 The general public should be informed…  Valuing without knowledge makes no sense  Thyroid Eye Disease  Give description of the disease A patient with bilateral thyroid eye disease with upper lid retraction and exophthalmos.

10 …or use validated questionnaires MOBILITY  I have no problems in walking about  I have some problems in walking about  I am confined to bed SELF-CARE  I have no problems with self-care  I have some problems washing or dressing myself  I am unable to wash or dress myself USUAL ACTIVITIES (e.g. work, study, housework family or leisure activities)  I have no problems with performing my usual activities  I have some problems with performing my usual activities  I am unable to perform my usual activities PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate pain or discomfort  I have extreme pain or discomfort ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately anxious or depressed  I am extremely anxious or depressed

11 Validated Questionnaires  Describe health states  Have values from the general public  Rosser Matrix  QWB  15D  HUI Mark 2  HUI Mark 3  EuroQol EQ-5D

12 Different perspective belong to different research questions  Health economics  Societal perspective General public  Medical decision making  Patients perspective  Epidemiology  Doctors perspective Global Burden of Disease